Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.
This review highlights the progress and gaps in pharmacological treatments for HSDD, emphasizing the need for standardized trial methodologies and comprehensive reporting.
Where it sits
this study against the rest of the pt-141 (bremelanotide) corpusSummary and findings
This systematic review evaluated completed clinical trials on pharmacological therapies for hypoactive sexual desire disorder (HSDD) in adult women. The review included nine trials, primarily focusing on agents like flibanserin and bremelanotide. The findings indicate variability in trial design and reporting practices, affecting the interpretation of efficacy and safety.
Abstract
<h4>Background</h4>Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting adult women and is associated with significant impairments in quality of life and interpersonal relationships. Despite increasing recognition of female sexual health as a clinical priority, pharmacological treatment options for HSDD remain limited, and evidence from individual clinical trials remains heterogeneous. Therefore, a systematic evaluation of registered clinical trials is essential to better understand therapeutic development, efficacy endpoints, and safety profiles of emerging treatments.<h4>Methods</h4>This systematic review was conducted in accordance with PRISMA 2020 guidelines using a structured search of ClinicalTrials.gov. Completed interventional clinical trials evaluating pharmacological therapies for HSDD in adult women were identified using predefined eligibility criteria. Data were extracted on study design, participant characteristics, investigational agents, efficacy outcomes related to sexual desire and distress, and reported safety outcomes. Findings were synthesized descriptively without pooled quantitative analysis.<h4>Results</h4>A total of nine completed pharmacological clinical trials met the inclusion criteria. Most were Phase II and Phase III randomized, double-blind, placebo-controlled studies, primarily enrolling premenopausal women with acquired, generalized HSDD. Investigational therapies predominantly targeted central nervous system pathways, with flibanserin and bremelanotide representing the most extensively studied agents. Efficacy outcomes commonly included validated patient-reported measures such as the Female Sexual Function Index desire domain and the Female Sexual Distress Scale; however, endpoint designation and reporting completeness varied across trials. Safety data were inconsistently reported, with adverse events reflecting the pharmacological mechanisms of the agents studied.<h4>Conclusion</h4>The findings highlight both progress and persistent gaps in the pharmacological treatment landscape for HSDD. Variability in trial design, outcome measures, and reporting practices limits cross-trial comparison and clinical interpretation. Further research with standardized methodologies and comprehensive reporting is needed to strengthen the evidence base.
Background
This paper addresses the clinical question of effective pharmacological therapies for hypoactive sexual desire disorder (HSDD) in women, a condition characterized by a lack of sexual desire. Prior research has identified various treatment options, but the efficacy and safety of these therapies remain under investigation. This systematic review is significant as it consolidates findings from multiple studies to provide a clearer picture of available treatments.
Methods
The study design is a systematic review of clinical trials registered on ClinicalTrials.gov, focusing on completed studies related to HSDD in women. The specific population, sample size, doses, and duration of treatments for PT-141 were not reported in the abstract. Primary and secondary outcome measures were not detailed.
Results
Not reported in abstract.
Interpretation
Due to the lack of specific data regarding PT-141 in the abstract, it is challenging to compare its efficacy with prior literature or assess its clinical significance. Without detailed results, the implications for practice remain unclear, and potential confounds such as study design and population characteristics cannot be evaluated.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.